基于处方点评的中成药临床合理用药关键要素分析探究

Analysis and Research on Key Elements of Clinical Rational Use of Chinese Patent Medicines Based on Prescription Reviews

目的评价基于处方点评的中成药临床合理用药关键要素。方法研究区间为2019年6月至2021年7月,选择我院在此期间开具的中成药处方进行研究分析,2020年6月之前的处方(对照组)共1 200张未采取任何干预,2020年7月至2021年7月的处方(观察组)共1 200张采取中成药处方点评,分析评价干预前后中成药处方不合理情况发生率、临床不良事件发生率以及患者的用药满意度。结果对照组处方发生不合理用药现象的概率为10.33%,观察组干预后出现不合理用药概率为7.25%,对比差异有统计意义,P <0.05,造成中成药处方不合理现象的原因与适应证不适宜、书写不规范、用法用量不适宜、联合用药不适宜以及遴选药品不适宜等有关。观察组处方患者的用药总满意度显著高于对照组,药品剂量纠纷、使用方法纠纷和药品遴选纠纷发生率明显低于对照组,对比差异有显著性,P <0.05。结论在中成药临床应用指导中开展科学的处方点评工作,不仅能降低不合理用药发生率,还能维护良好的用药环境,减少医疗纠纷的发生,值得临床采纳应用。

Objective To evaluate the key elements of the clinical rational use of Chinese patent medicines based on prescription reviews. Methods The study period is from June 2019 to July 2021. The prescriptions of Chinese patent medicines issued by our hospital during this period are selected for research and analysis. A total of 1 200 prescriptions(control group) before June 2020 are not taken any intervention. 2020 From July 2005 to July 2021(observation group), a total of 1 200 prescriptions of Chinese patent medicines were reviewed, and the incidence of unreasonable prescriptions of Chinese patent medicines before and after the intervention, the incidence of clinical adverse events, and the patient’s medication satisfaction were analyzed and evaluated. Results The probability of irrational use of prescriptions in the control group was 10.33%, and the probability of irrational use of drugs in the observation group after intervention was 7.25%. The difference was statistically significant, P <0.05, the reason and adaptation of the irrational prescription of Chinese patent medicines inappropriate symptoms, improper writing, improper usage and dosage, unsuitable combination medication, and unsuitable selection of drugs;the total satisfaction of prescription patients in the observation group was significantly higher than that of the control group, and their drug dosage disputes, use method disputes, and drugs the incidence of selection disputes was significantly lower than that of the control group, the difference was significant, P<0.05.Conclusion Carrying out scientific prescription review work in the clinical application of Chinese patent medicines can not only reduce the incidence of irrational use of drugs, but also maintain a good medication environment and reduce the occurrence of medical disputes. It is worthy of clinical adoption and application.